CA2627638A1 - Reproduction conditionnelle de virus et methodes pour virotherapie de cancers - Google Patents

Reproduction conditionnelle de virus et methodes pour virotherapie de cancers Download PDF

Info

Publication number
CA2627638A1
CA2627638A1 CA002627638A CA2627638A CA2627638A1 CA 2627638 A1 CA2627638 A1 CA 2627638A1 CA 002627638 A CA002627638 A CA 002627638A CA 2627638 A CA2627638 A CA 2627638A CA 2627638 A1 CA2627638 A1 CA 2627638A1
Authority
CA
Canada
Prior art keywords
sequence
virus
composition
cells
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002627638A
Other languages
English (en)
Inventor
Michael James Mathis
Arrigo Debenedetti
David T. Curiel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2627638A1 publication Critical patent/CA2627638A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/002—Vectors comprising a special origin of replication system inducible or controllable

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CA002627638A 2005-10-28 2005-10-28 Reproduction conditionnelle de virus et methodes pour virotherapie de cancers Abandoned CA2627638A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2005/038918 WO2007050074A1 (fr) 2005-10-28 2005-10-28 Reproduction conditionnelle de virus et méthodes pour virothérapie de cancers

Publications (1)

Publication Number Publication Date
CA2627638A1 true CA2627638A1 (fr) 2007-05-03

Family

ID=37968085

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002627638A Abandoned CA2627638A1 (fr) 2005-10-28 2005-10-28 Reproduction conditionnelle de virus et methodes pour virotherapie de cancers

Country Status (5)

Country Link
EP (1) EP1948792A4 (fr)
JP (1) JP2009513133A (fr)
AU (1) AU2005337612A1 (fr)
CA (1) CA2627638A1 (fr)
WO (1) WO2007050074A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104814984B (zh) * 2014-08-26 2017-09-15 广州威溶特医药科技有限公司 甲病毒在制备抗肿瘤药物方面的应用
EP3987028A4 (fr) * 2019-06-21 2023-07-19 Kernal Biologics, Inc. Expression de protéine oncosélective modifiée

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017138A1 (en) * 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
AU4250600A (en) * 1999-04-21 2000-11-02 Genzyme Corporation Adenoviral vectors having nucleic acids encoding immunomodulatory molecules
US6759394B2 (en) * 2001-07-26 2004-07-06 Board Of Supervisors Of La. State Un. & Agricultural And Mechanical College Cancer gene therapy based on translational control of a suicide gene

Also Published As

Publication number Publication date
WO2007050074A1 (fr) 2007-05-03
AU2005337612A1 (en) 2007-05-03
AU2005337612A8 (en) 2008-07-03
EP1948792A1 (fr) 2008-07-30
EP1948792A4 (fr) 2010-08-04
JP2009513133A (ja) 2009-04-02

Similar Documents

Publication Publication Date Title
US7048920B2 (en) Recombinant oncolytic adenovirus for human melanoma
CA2640528C (fr) Adenovirus oncolytiques destines au traitement du cancer
Tsukuda et al. An E2F-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell
US10538744B2 (en) Use of adenovirus and nucleic acids coding therefor
Cody et al. Armed replicating adenoviruses for cancer virotherapy
ES2557812T3 (es) Mutantes de E1a y E1b de adenovirus selectivos de tumor
CN109576231B (zh) 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
US20090270485A1 (en) Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
JP2011200234A (ja) 新規アデノウイルス、それをコードする核酸及びその使用
JP4361708B2 (ja) 複製−コンピテント抗癌ベクター
Kim et al. Antitumoral effects of recombinant adenovirus YKL-1001, conditionally replicating in α-fetoprotein-producing human liver cancer cells
WO2012163119A1 (fr) Construction et application d'un adénovirus humain de type b ad11 mutant ayant un pouvoir oncolytique amélioré
CN101565718A (zh) 三靶向嵌合型溶瘤腺病毒Ad5/F11载体的构建方法及其应用
US20060275262A1 (en) Conditionally replicating viruses and methods for cancer virotherapy
Gao et al. RETRACTED: Selective Targeting of Checkpoint Kinase 1 in Tumor Cells with a Novel Potent Oncolytic Adenovirus
Sutter et al. Gene therapy for gastric cancer: is it promising?
Matthews et al. Advancements in adenoviral based virotherapy for ovarian cancer
Sonabend et al. Conditionally replicative adenoviral vectors for malignant glioma
CA2627638A1 (fr) Reproduction conditionnelle de virus et methodes pour virotherapie de cancers
WO2004042025A2 (fr) Vecteur d'adenovirus specifique des cellules comprenant un promoteur specifique de ebv
RU2814581C1 (ru) Генетический вектор Ad6/3-hTERT-GMCSF, содержащий геномные последовательности рекомбинантного аденовируса 6 серотипа, промотор теломеразы человека, ген гранулоцитарно-макрофагального колониестимулирующего фактора человека, а также ген белка файбер со встройкой домена fiber knob аденовируса 3 серотипа, обладающий повышенной трансдукцией в опухолевые клетки
CN113774031B (zh) 一种复制型人腺病毒及其应用
Tong Oncolytic viral therapy for human cancer: challenges revisited
CN101880688B (zh) 一种使复制缺陷型腺病毒选择性复制的方法和用途
TWI391486B (zh) 新穎啟動子及包含其之病毒載體

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead